Literature DB >> 19962305

Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology.

Hiroshi Nagase1, Akio Watanabe, Toru Nemoto, Noriyuki Yamaotsu, Kohei Hayashida, Mayumi Nakajima, Ko Hasebe, Kaoru Nakao, Hidenori Mochizuki, Shuichi Hirono, Hideaki Fujii.   

Abstract

A conformational analysis of kappa opioid receptor agonists, TRK-820 and U-50,488H indicated an active conformation of TRK-820 in which the C-ring was in the boat form with the 14-OH interacting with the amide nitrogen. Based on the obtained active conformation of TRK-820, we designed and synthesized a novel kappa agonist KNT-63 with oxabicyclo[2.2.2]octane skeleton. KNT-63 showed profound antinociceptive effects via the kappa receptor which were as potent as that of TRK-820. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19962305     DOI: 10.1016/j.bmcl.2009.11.027

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  3 in total

1.  Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor.

Authors:  Selena S Schattauer; Jamie R Kuhar; Allisa Song; Charles Chavkin
Journal:  Cell Signal       Date:  2017-01-11       Impact factor: 4.315

2.  Synthesis and pharmacological activities of 6-glycine substituted 14-phenylpropoxymorphinans, a novel class of opioids with high opioid receptor affinities and antinociceptive potencies.

Authors:  Mariana Spetea; Petra Windisch; Yan Guo; Indre Bileviciute-Ljungar; Johannes Schütz; Muhammad Faheem Asim; Ilona P Berzetei-Gurske; Pal Riba; Kornel Kiraly; Susanna Fürst; Mahmoud Al-Khrasani; Helmut Schmidhammer
Journal:  J Med Chem       Date:  2011-01-14       Impact factor: 7.446

3.  Structurally Related Kappa Opioid Receptor Agonists with Substantial Differential Signaling Bias: Neuroendocrine and Behavioral Effects in C57BL6 Mice.

Authors:  Amelia D Dunn; Brian Reed; Catherine Guariglia; Alexandra M Dunn; Joshua M Hillman; Mary Jeanne Kreek
Journal:  Int J Neuropsychopharmacol       Date:  2018-09-01       Impact factor: 5.176

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.